亚盛医药(06855.HK)料未来5年为药品商业化高峰期
亚盛医药(06855.HK)今日在主板上市,联合创始人兼首席执行官杨大俊在上市仪式後表示,公司有8项处临床阶段的小分子候选药物,其中核心药物「HQP1351」的关键二期临床试验持续,公司计划明年为该药申请上市注册许可,如临床数据满意及获监管批准,最快可於2021年商业化,至於其他药品的商业化高峰期预期在未来5年。
公司是次上市引入中生制药(01177.HK)作为基石投资者,认购相当於2,000万美元股份。杨大俊称未来与中生有很多机会探讨合作空间,但是次对方是以投资者身份入股。对於内地近年持续调整对医药行业的政策,他指国家医药政策为支持创新药,政策调控主要针对仿制药,相信公司研发的药品会有很好保证。 ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.